French research network for kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The UroCCR database is a national network in France focused on improving therapeutic management and conducting applied research in kidney cancer. It collects extensive data on patient cases, including over a thousand variables related to disease presentation and evolution, along with biological samples such as plasma, urine, and tumor tissues. This multicentric and multidisciplinary approach aims to evaluate and compare various surgical techniques and drug treatments for kidney cancer, enhancing the understanding of effective management strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient with kidney cancer
* Patient with no opposition to collection of its data for the study

Exclusion Criteria: none

Where it's running

• CHU Angers
  Angers, France Recruiting
• CHU Bordeaux
  Bordeaux, France Recruiting
• Clinique TIVOLI-DUCOS
  Bordeaux, France Recruiting
• Polyclinique Médipôle Saint-Roch_Cabestany
  Cabestany, France Recruiting
• CHU Caen
  Caen, France Recruiting
• CHU de Clermont-Ferrand
  Clermont-Ferrand, France Recruiting

+18 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Jean-Christophe BERNHARD, PHU — University Hospital, Bordeaux
• Study coordinator: Jean-Christophe BERNHARD, PHU
• Email: jean-christophe.bernhard@chu-bordeaux.fr
• Phone: +33 (0)5 57 82 03 50

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Perioperative UDCA to Protect Kidney Function in Partial Nephrectomy

  This study tests whether giving ursodeoxycholic acid around surgery can help protect kidney function in adults having partial nephrectomy for kidney tumors.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07672860

• Side Effects and Resource Navigation Program for Cancer Patients

  This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07646847

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• HC-7366 plus nivolumab with or without ipilimumab for advanced clear-cell kidney cancer (SHARK)

  This trial tests whether adding HC-7366 to nivolumab, with or without ipilimumab, can help control advanced clear-cell kidney cancer.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Dallas, Texas and 1 other locations · NCT07401875

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.